Sorrento therapeutics

Beleggen in aandelen beurs New York, Dow Jones, Nasdaq-100 en S&P500

ancaoli
Forum veteraan
Forum veteraan
Berichten: 1707
Lid geworden op: 28 jan 2018 18:54
waarderingen: 894
Contacteer:

Re: Sorrento therapeutics

Bericht door ancaoli »

Voila, 1 u meegeluisterd maar zoals gevreesd niets nieuws. We gaan nog een beetje geduld moeten hebben voor de funding en approvals. Uiteraard gaan de shorters dit nu uitbuiten dus sterke KT koersdaling is perfect mogelijk :(
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Argenx, Agfa, Ontex, OCI, Sorrento, Inventiva







Volg Beursig.com op Twitter en Facebook


ancaoli
Forum veteraan
Forum veteraan
Berichten: 1707
Lid geworden op: 28 jan 2018 18:54
waarderingen: 894
Contacteer:

Re: Sorrento therapeutics

Bericht door ancaoli »

Met dank aan Gary van Yahoo:

conference call notes 1. Sti 1499 PRIORITIZE by FDA for stage-1 30 pts mod-severe for USA and eminently 500pts Brazil. also less than 200mg- less expensive and greater doses 2. sti5656 Abivertib cleared for phase 2 also eminent Brazil approval 400pts plus cleared for eua for 600pts. of course for Cancer completed phase 3 and data being given to FDA. 3. civiguard sti 1499 was most powerful on market, targeted antibody designed to avoid side effects 4. sti 2020 50-80 times MORE POWERFUL than 1499 and one step behind. They wont be combines together but with complimenting antibody. rescue tx. 5. Small molecule can complement everything and systematic. 6. Stem cell IV infusion cleared for 20 pts in California stage 1 and testing being prepared for cytokine storm will #$%$ with multiple site with positive data. 7. Sti 2020 FDA filing for mid Nov for severe cases. 8 Intranasal being explored includes small molecule use. 9 plasma DNA delivered into muscle could be in micrograms and create antibodies in process 10. Covid Track Igg/Igm antibody testing 8min is under review by FDA and approval expected. 11. covitrace submitted by Columbia with excellent results, delay is secondary submission for entire systematic testing etc, but is fully expecting approval and bankning on it with 2nd eua super eminent for submission. It is super sensitive best on market for saliva greater that 96% accurate 12. CoviStix most senstive even non symptomatic. outer nasal or siliva not deep nasal. for home, sports, travel, etc screening in minutes. FDA priority and submission eminent 13. Sti 2020 with 2099 could be given IM or IVP at 10x less cost. 14 Brazil "cusp" of approval. 15 Scilex distributor network and more being explored. 16 Antibodies EFFECTIVE on all mutations and vaccines may be limited plus addresses reinfection. 17 BARDA funding and other funding being pursued and VERY HAPPY with response- needs final hurdle of approval. 18. expect large revenues from RTX 2021 pain line. 19 basically production ability probably near CAPACITY of large companies as long as they are stuck on huge doses. 50,000 doses initial, 100,000/mo after that 2021 expect millions/mo. 20. Cancer line on going and not focused on NON NARCOTIC pain solutions by epidural and knee injections. Rest of SRNE line for cancer active and may get R and D day as well. OVERALL GREAT PROGRESS ON TRACK, SOME EMINENTLY APPROVALS ANYDAY OTHER SLIGHTLY FARTHER OUT, EXPECTATIONS ARE HIGH!
sepan liked last!
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Argenx, Agfa, Ontex, OCI, Sorrento, Inventiva

Gentse strop
Forum actieveling
Forum actieveling
Berichten: 674
Lid geworden op: 06 jun 2012 16:57
waarderingen: 305
Contacteer:

Re: Sorrento therapeutics

Bericht door Gentse strop »

ancaoli schreef:
14 okt 2020 08:28
OVERALL GREAT PROGRESS ON TRACK, SOME EMINENTLY APPROVALS ANYDAY OTHER SLIGHTLY FARTHER OUT, EXPECTATIONS ARE HIGH!
Veel bla bla bla, maar tot nog toe weinig facts! Zit erin maar hekel hun werkwijze!

alwaysright
Forum actieveling
Forum actieveling
Berichten: 921
Lid geworden op: 10 mei 2013 19:25
waarderingen: 362
Contacteer:

Re: Sorrento therapeutics

Bericht door alwaysright »

Er gebeurt wel iets....

Healthcare | On the Move
Sorrento Therapeutics awarded antibodies patents
Oct. 13, 2020 3:29 PM ET|About: Sorrento Therapeutics, Inc. (SRNE)|By: Stephen Alpher, SA News Editor
The U.S. Patent Office has awarded Sorrento Therapeutics (NASDAQ:SRNE) patents for 1) Antibody therapeutics that bind CD38, and 2) Disulfide bridging conjugates.

Timroels
Forum verkenner
Forum verkenner
Berichten: 26
Lid geworden op: 18 mei 2020 19:53
waarderingen: 6
Contacteer:

Re: Sorrento therapeutics

Bericht door Timroels »

Zoude misschien beter eens een vacature plaatsen voor een pers verantwoordelijke. Alle begrip ma zijn engels slaagt op niks soms:..

beurssukkel
Forum actieveling
Forum actieveling
Berichten: 359
Lid geworden op: 03 nov 2015 16:17
waarderingen: 96
Contacteer:

Re: Sorrento therapeutics

Bericht door beurssukkel »

Timroels schreef:
14 okt 2020 09:45
Zoude misschien beter eens een vacature plaatsen voor een pers verantwoordelijke. Alle begrip ma zijn engels slaagt op niks soms:..

Idd, taal is een barometer :wtf:

Stefkamielkafkajr
Forum actieveling
Forum actieveling
Berichten: 782
Lid geworden op: 25 dec 2013 21:48
waarderingen: 253
Contacteer:

Re: Sorrento therapeutics

Bericht door Stefkamielkafkajr »

blijkbaar gaan we hier naar een donker rode opening gaan
gisteren na uren doorgezakt naar 9.80$ om te eindigen rond10.20$

zouden de shorters terug aan het werk zijn :down:
Altice europe,aegon,, euronav, acacia pharma,fagron,,, greenyard ,pharming, , econocom.Xfab.oxurion.sorrento therapeutics.luckin coffe adr

alwaysright
Forum actieveling
Forum actieveling
Berichten: 921
Lid geworden op: 10 mei 2013 19:25
waarderingen: 362
Contacteer:

Re: Sorrento therapeutics

Bericht door alwaysright »

We weten dat dit aandeel 29.5% geshort wordt,dan kan je op je vingers natellen dat die gasten gisteren met dichtgeknepen billen die conferentie hebben gevolgd.Als er dan niet direct spectaculair nieuws naar buiten komt dan grijpen die gasten dit aan als zwaar tegenvallend nieuws,gooien een hoop in de verkoop in de hoop dat de hele meute meegaat.
We zullen zien in hoeverre dit spelletje doorzien wordt,tijdens dit schrijven voorbeurs bijna $11...
Geen paniek,er zijn nu al meerdere fabrikanten die hun Covid producten on hold hebben gezet,en Dr JI heeft vanaf het begin al gezegd dat ze gelijk met een goed werkend middel op de markt willen komen...we zullen zien
Stefkamielkafkajr liked last!

ancaoli
Forum veteraan
Forum veteraan
Berichten: 1707
Lid geworden op: 28 jan 2018 18:54
waarderingen: 894
Contacteer:

Re: Sorrento therapeutics

Bericht door ancaoli »

Bij sterke daling zie ik in huidige context een koopopportuniteit. Fundamenteel lijken ze goed bezig. Hun communicatie schort wel nog wat. De antwoorden die ze gisteren op de vragen gaven vond ik van matige kwaliteit, het Engels van Ji blijft ook een probleem. Wel positief dat ze beginnen met communicatie; het blijft nog wat onprofessioneel maar alle begin is moeilijk.
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Argenx, Agfa, Ontex, OCI, Sorrento, Inventiva

manu47
Forum gebruiker
Forum gebruiker
Berichten: 106
Lid geworden op: 11 apr 2013 13:35
waarderingen: 35
Contacteer:

Re: Sorrento therapeutics

Bericht door manu47 »

Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients

October 14, 2020 at 11:57 AM EDT
Download PDF
Phase 2 clinical trials of Abivertinib now cleared to proceed in both Brazil and the U.S.
Studies are complementary and address both dose duration and disease stage
Rapid enrollment expected for both geographies

SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 clinical trial of Abivertinib in mild, moderate and severe COVID-19 patients.

The Brazil study is a Phase 2, Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19, particularly looking at the potential clinical benefits of the drug associated with its broad ability (mode of action) to reduce inflammatory cytokine storm. The dose to be tested is the same as in the U.S. Phase 2 trial, but the trial protocol in Brazil includes patients at earlier stages of the disease, with a drug administration regimen of only 7 days (versus 14 days for more advanced patients in the U.S.).

The Brazilian study is expected to rapidly enroll 400 patients. The rapid projected enrollment pace is made possible by the recent partnership established between Sorrento and a leading local clinical research organization (Synova Health) with access to high quality medical centers throughout the country.

A broad clinical development strategic alignment between Sorrento and local medical systems, including with the city of Rio de Janeiro, will also help accelerate site initiation and access to potential patients for additional Sorrento studies currently being evaluated by ANVISA.

BR Protocol Design U.S. Protocol Design
Mild, Moderate and Severe COVID-19 patients Severe COVID-19 patients
Any hospitalized patient ICU non-ventilated
N=400 randomized 3:1 (Abivertinib to placebo) N=80 randomized 1:1 (Abivertinib to placebo)
100 mg QD x 7 days 100 mg QD x 14 days
Duration 45 days Duration 94 days
Primary endpoint:
% discharged from hospital by Week 4 Primary endpoint:
% alive and free of respiratory failure at Week 4
“We are very satisfied with the progress made in Brazil so far,” stated Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics. “By targeting some of the geographies currently most impacted by COVID-19, we are able to implement a synergistic program to answer questions about safety and efficacy of our drug candidates in helping patients, while potentially accelerating enrollment timelines, reducing overall cost and opening up collaboration opportunities with local companies.”

The study is referenced with ANVISA (Brazilian authority) under Process nº 25351.105670/2020-14, Reference n° 3380614/20-4

Brazilian Clinical Study details can be found at:
https://clinicaltrials.gov/ct2/show/NCT ... w=2&rank=3

About Sorrento Therapeutics, Inc.
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB™ library"), clinical stage immuno-cellular therapies ("CAR-T", "DAR-T"), antibody-drug conjugates ("ADCs"), and clinical stage oncolytic virus ("Seprehvir®", “Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™, COVI-AMG™ and T-VIVA-19™; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ("RTX"), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a phase 1B trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on February 28, 2018.

For more information, visit www.sorrentotherapeutics.com

Forward-Looking Statements
This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Abivertinib, including the safety, tolerability and demonstrated efficacy thereof; the potential ability of Abivertinib to reduce inflammatory cytokine activity; expected rapid enrollment of clinical trials in the U.S. and Brazil; the protocol design for both the U.S. and Brazilian clinical trials; the synergistic potential of the U.S. and Brazil clinical trials; and the ability of a synergistic program to potentially accelerate enrollment timelines, reduce overall cost and create collaboration opportunities with local companies . Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento’s and its subsidiaries’, affiliates’ and partners’ technologies and prospects and collaborations with partners, including, but not limited to clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its therapeutic product candidates strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento’s most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Contact
Alexis Nahama, DVM (SVP Corporate Development)
Email: mediarelations@sorrentotherapeutics.com

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.
G-MAB™, COVI-GUARD™, COVI-SHIELD™, COVI-AMG™, COVIDTRAP™, T-VIVA-19™, COVI-MAB™, ACE-MAB™, COVI-TRACK™, COVI-STIX™ and COVI-TRACE™ are trademarks of Sorrento Therapeutics, Inc.

ZTlido® is a trademark owned by Scilex Pharmaceuticals Inc.
All other trademarks are the property of their respective owners.
© 2020 Sorrento Therapeutics, Inc. All Rights Reserved.


15-SORRENTO-Therapeutics-Logo-FINAL.png

Source: Sorrento Therapeutics, Inc.
believer liked last!
C50, IWDA, CP9, CJ1, Ontex, Mytilineos, EVS, Moury Construct, CK Asset Holding, NN, Nationale Bank, FNG, NEL ASA, Innate Pharma, Kiadis, Biocartis, KKO, Exmar, Acacia Pharma, Transgene, Pharming, Galapagos, Celyad, Smartphoto, Orange Belgium, iA Financial, Econocom


Deelnemen aan het forum + meer functies?

Deel kennis en vragen met duizenden beleggers,
minder advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!



Plaats reactie